The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > BUSINESS
BUSINESS
- Meiji Seika Pharma Poised to Get Lion’s Share in Antidepressant Market
November 10, 2014
- Bayer, Kyoto Univ. to Hold First Collaborative Meeting by March
November 7, 2014
- Sales of Four Major Wholesalers Hit by Drop in Long-Listed Product Sales
November 7, 2014
- Ono to Copromote Opdivo with Bristol-Myers in Japan: President
November 7, 2014
- Trebananib Fails to Demonstrate Improvement in OS in PIII Study for Recurrent Ovarian Cancer: Takeda
November 7, 2014
- Toray Medical Files Nalfurafine for Pruritus Associated with Chronic Hepatic Disease
November 7, 2014
- Daiichi Sankyo to Cut Japan Jobs to Brace for Olmetec Patent Expiry
November 6, 2014
- Lorcaserin Confirms POC as Potential Smoking Cessation Aid in PII Study in US: Eisai
November 6, 2014
- Alfresa Transfers Part of Shares of Vaccine-Related Subsidiary to 5 Drug Makers
November 6, 2014
- LEO Pharma to Develop JT’s JAK inhibitor for Skin Disorders Outside Japan
November 6, 2014
- Overseas Growth Boosts Combined Sales of Four Major Drug Makers
November 6, 2014
- Sawai Wins Livalo Trademark Suit
November 6, 2014
- Astellas, Dana-Farber Cut Deal on KRAS Inhibitor Development
November 6, 2014
- Astellas Ties Up with US Biotech on Therapies Modulating Unfolded Protein Response
November 6, 2014
- Terumo Seeks Japan Approval of Cell Sheets for Severe Heart Failure
November 6, 2014
- Takeda, Intra-Cellular Therapies End Collaboration on PDE1 Inhibitors
November 6, 2014
- US FDA Advisory Committee Backs Approval of Edoxaban: Daiichi Sankyo
November 6, 2014
- Kyowa Kirin Completes Construction of New Product Manufacturing Facility at Takasaki Plant
November 5, 2014
- Daiichi Sankyo Posts 30.6% Rise in First-Half Operating Profit, 1.7% in Revenue
November 4, 2014
- Sumitomo Dainippon Will Stick to FY2017 Earnings Targets despite BBI608 Setback: Pres.
November 4, 2014
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…